| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents, including restricted cash of 152 for both periods presented | 64,290 | 60,474 | ||
| Trade receivables, net of allowances of 137 and 95, respectively | 8,506 | 9,656 | ||
| Inventories | 18,791 | 14,406 | ||
| Prepaid expenses and other assets | 2,029 | 2,143 | ||
| Total current assets | 93,616 | 86,679 | ||
| Leasehold improvements and equipment, net | 1,499 | 1,632 | ||
| Intangible assets, net | 246 | 284 | ||
| Right-of-use assets, net | 2,361 | 2,525 | ||
| Other long-term assets | 417 | 405 | ||
| Total assets | 98,139 | 91,525 | ||
| Accounts payable | 12,742 | 13,680 | ||
| Accrued expenses | 8,700 | 7,381 | ||
| Current maturities of operating lease obligations | 976 | 957 | ||
| Current maturities of finance lease obligations | 2 | 6 | ||
| Customer deposits | 292 | 303 | ||
| Total current liabilities | 22,712 | 22,327 | ||
| Deferred revenue | 2,674 | 2,674 | ||
| Operating lease obligations, less current maturities | 2,077 | 2,329 | ||
| Total liabilities | 27,463 | 27,330 | ||
| Common stock, 0.001 par value authorized 150,000 shares 79,639 shares and 77,330 shares issued and outstanding at september30, 2025 and december31, 2024, respectively | 79 | 79 | ||
| Additional paid-in capital | 239,266 | 237,358 | ||
| Accumulated deficit | -168,660 | -173,238 | ||
| Cumulative translation adjustments | -9 | -4 | ||
| Total stockholders' equity | 70,676 | 64,195 | ||
| Total liabilities and stockholders' equity | 98,139 | 91,525 | ||
Niagen Bioscience, Inc. (NAGE)
Niagen Bioscience, Inc. (NAGE)